# METTL3 blocked the progression of diabetic retinopathy through m6A-modified SOX2

**Authors:** Xiujuan Chen, Qipeng Ling, Jie Xu, Yunyao Ye, Lili Dong

PMC · DOI: 10.1515/med-2025-1191 · Open Medicine · 2025-07-25

## TL;DR

This study shows that METTL3 helps prevent diabetic retinopathy by modifying SOX2 mRNA, reducing cell death in retinal cells.

## Contribution

The novel finding is that METTL3 blocks diabetic retinopathy progression via m6A modification of SOX2 mRNA.

## Key findings

- METTL3, IGF2BP2, and SOX2 levels are reduced in diabetic retinopathy patients and high-glucose-treated retinal cells.
- METTL3 upregulation reduces high-glucose-induced retinal cell apoptosis and restores cell viability.
- SOX2 knockdown partially reverses the protective effects of METTL3 in retinal cells.

## Abstract

We aimed to explore the regulatory effects of methyltransferase-like 3 (METTL3) on diabetic retinopathy (DR) by regulating the m6A modification of SOX2 mRNA and elucidating the underlying molecular mechanism. The DR model was established by stimulating human retinal endothelial cells (HRECs) with high glucose (HG). METTL3, insulin-like growth factor 2 binding protein 2 (IGF2BP2), and SOX2 levels in the sera of patients with DR and HRECs were determined using qRT-PCR and western blotting. Moreover, the interactions between SOX2 and METTL3 or IGF2BP2 were confirmed using RNA-binding protein immunoprecipitation (RIP) experiments. Furthermore, HRECs proliferation and apoptosis were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry, respectively. The protein level of cleaved-caspase3 and caspase3 in HRECs were evaluated using western blotting. The results indicated that the expression of METTL3, IGF2BP2, and SOX2 was notably decreased in the serum of patients with DR, as well as in HRECs under HGs. RIP further verified the relationship between METTL3 and SOX2 mRNA expression. HG treatment inhibited HREC viability, increased apoptosis, and enhanced cleaved-caspase3 expression and cleaved-caspase3/caspase3 ratio. Upregulation of METTL3 significantly restored the effects of HG, whereas SOX2 knockdown partially reversed the regulatory effects of METTL3 on HRECs. In summary, METTL3 blocks the progression of DR by regulating m6A modification on SOX2 mRNA.

## Linked entities

- **Genes:** METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339], IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644], SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657]
- **Proteins:** METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit), IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2), SOX2 (SRY-box transcription factor 2), Casp3 (caspase 3)
- **Chemicals:** 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (PubChem CID 64965)
- **Diseases:** diabetic retinopathy (MONDO:0005266)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644] {aka IMP-2, IMP2, VICKZ2}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}
- **Diseases:** DR (MESH:D003930)
- **Chemicals:** MTT (MESH:C070243), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MESH:C022616), m6A (MESH:C005955), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12301709/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12301709/full.md

---
Source: https://tomesphere.com/paper/PMC12301709